Inactive Instrument

Biocorrx Inc Stock Other OTC

US09073C1062

Healthcare Facilities & Services

BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	6.35M 5.75M 5.32M 4.8M 9.05M 599M 9.37M 63.94M 25.35M 320M 23.83M 23.32M 1.02B	P/E 2024	-0.78x	P/E 2025	-1.56x
Enterprise Value	8.35M 7.57M 7M 6.32M 11.9M 787M 12.32M 84.09M 33.34M 421M 31.34M 30.68M 1.34B	EV / Sales 2024	1,004x	EV / Sales 2025	11.4x
Free-Float	40.09%	Yield 2024 *	-	Yield 2025	-

09-10	Biocorrx Inc Announces Appointment of Richard J. Baum to Strategic Advisory Board	CI
09-04	BioCorRx Inc. Announces Resignation of Kate Beebe Devarney as Member of the Board of Directors, Effective August 31, 2026	CI
08-14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
11-15	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/08/25	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/07/25	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
16/05/25	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
31/03/25	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI

12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/04/24	BioCorRx Reports Business Update for 2023	AQ

Manager	Title	Age	Since
Lourdes Felix CEO	Chief Executive Officer	58	09/11/2020
Louis Lucido PSD	President	77	05/01/2024

Director	Title	Age	Since
Lourdes Felix BRD	Director/Board Member	58	07/03/2013
Kent Emry CHM	Chairman	57	-
Louis Lucido BRD	Director/Board Member	77	01/03/2019

Biocorrx Inc Stock Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

Valuation: Biocorrx Inc

Latest news: Biocorrx Inc

Press Releases: Biocorrx Inc

Quotes and Performance

Managers and Directors: Biocorrx Inc

Other Healthcare Facilities & Services

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORRX INC	-15.84%	+6.09%	-	-	6.08M
CVS HEALTH CORPORATION	-0.49%	+6.56%	+12.76%	+31.78%	115B
HCA HEALTHCARE, INC.	-0.32%	+0.82%	+5.44%	+116.99%	105B
NATERA, INC.	-1.19%	+2.71%	+59.01%	+557.38%	46.83B
FRESENIUS SE & CO. KGAA	+0.89%	+1.54%	+8.69%	+105.75%	33.19B
LABCORP HOLDINGS INC.	-0.49%	+1.07%	+38.31%	+81.24%	30.23B
QUEST DIAGNOSTICS INCORPORATED	-0.02%	+1.55%	+38.39%	+96.15%	28.57B
TENET HEALTHCARE CORPORATION	-0.29%	+0.95%	+45.44%	+421.29%	22.83B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+0.33%	-1.02%	-18.35%	-17.59%	19.92B
IHH HEALTHCARE	+1.15%	+2.99%	-3.88%	+34.63%	16.99B
Average	-1.63%	+0.50%	+20.65%	+158.62%	46B
Weighted average by Cap.	-0.27%	+1.72%	+19.01%	+144.86%

	2024	2025
Net sales	7.66K 6.95K 6.42K 5.8K 10.92K 723K 11.31K 77.18K 30.6K 386K 28.76K 28.15K 1.23M	797K 722K 668K 603K 1.14M 75.17M 1.18M 8.03M 3.18M 40.15M 2.99M 2.93M 127M
Net income	-5.11M -4.63M -4.28M -3.86M -7.28M -481M -7.53M -51.41M -20.39M -257M -19.16M -18.76M -816M	-3.44M -3.12M -2.88M -2.6M -4.9M -324M -5.08M -34.64M -13.73M -173M -12.91M -12.64M -550M
Net Debt	2.72M 2.46M 2.28M 2.06M 3.87M 256M 4.01M 27.37M 10.85M 137M 10.2M 9.98M 435M	2M 1.81M 1.68M 1.51M 2.85M 189M 2.95M 20.15M 7.99M 101M 7.51M 7.35M 320M